Profile data is unavailable for this security.
About the company
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies and precision positioning devices. Its Pharmaceuticals segment includes specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Its Kidney Care segment includes chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies.
- Revenue in USD (TTM)14.81bn
- Net income in USD-76.00m
- Incorporated1931
- Employees60.00k
- LocationBaxter International IncDF2-1W, ONE BAXTER PKWYDEERFIELD 60015United StatesUSA
- Phone+1 (847) 948-2000
- Fax+1 (302) 655-5049
- Websitehttps://www.baxter.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insulet Corp | 1.70bn | 206.30m | 11.64bn | 3.00k | 59.00 | 15.86 | 41.71 | 6.86 | 2.82 | 2.82 | 22.78 | 10.48 | 0.7014 | 1.43 | 6.00 | 565,700.00 | 8.53 | 2.71 | 10.26 | 3.14 | 68.35 | 65.81 | 12.16 | 4.28 | 2.62 | 40.74 | 0.659 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
| Shockwave Medical Inc | 730.23m | 147.28m | 12.34bn | 1.47k | 85.26 | 18.20 | 78.28 | 16.90 | 3.86 | 3.86 | 19.13 | 18.08 | 0.66 | 1.04 | 7.86 | 497,431.90 | 13.31 | 10.29 | 14.40 | 11.39 | 86.94 | 84.69 | 20.17 | 15.14 | 10.73 | 19.70 | 0.5226 | 0.00 | 49.11 | 126.45 | -31.81 | -- | 72.88 | -- |
| Hologic Inc | 3.97bn | 515.10m | 17.69bn | 6.99k | 35.84 | 3.80 | 21.04 | 4.46 | 2.10 | 2.10 | 16.13 | 19.84 | 0.447 | 2.70 | 5.90 | 567,854.10 | 5.80 | 11.40 | 6.48 | 13.38 | 55.44 | 60.29 | 12.98 | 20.95 | 3.18 | -- | 0.3565 | 0.00 | -17.12 | 4.61 | -64.98 | -- | 7.30 | -- |
| Cooper Companies Inc | 3.67bn | 290.80m | 17.97bn | 15.00k | 91.37 | 2.33 | 27.00 | 4.90 | 0.9896 | 0.9896 | 7.36 | 38.73 | 0.3108 | 1.77 | 5.95 | 244,420.00 | 2.47 | 10.06 | 2.68 | 11.34 | 66.09 | 65.54 | 7.93 | 29.00 | 1.08 | 4.92 | 0.2649 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 31.95 |
| Steris PLC | 5.41bn | 566.84m | 19.71bn | 17.00k | 35.18 | 3.07 | 17.28 | 3.65 | 5.67 | 5.67 | 54.18 | 64.93 | 0.4864 | 3.94 | 6.05 | 318,081.40 | 5.11 | 3.99 | 5.54 | 4.37 | 43.60 | 43.41 | 10.50 | 7.90 | 1.49 | 6.42 | 0.3399 | 49.05 | 8.13 | 13.61 | -56.12 | -17.02 | 16.95 | 8.74 |
| Baxter International Inc | 14.81bn | -76.00m | 20.10bn | 60.00k | -- | 2.38 | 16.84 | 1.36 | -0.1508 | 5.22 | 29.23 | 16.55 | 0.5238 | 3.43 | 5.48 | 246,883.30 | -0.244 | 0.1942 | -0.3054 | 0.2333 | 35.89 | 38.20 | -0.4658 | 0.3674 | 1.04 | 3.28 | 0.6197 | 1,398.94 | 2.12 | 5.94 | 97.15 | -- | 0.982 | 9.71 |
| Align Technology, Inc. | 3.86bn | 445.05m | 22.50bn | 21.61k | 51.42 | 6.18 | 38.30 | 5.83 | 5.81 | 5.81 | 50.43 | 48.36 | 0.642 | 3.64 | 4.38 | 178,725.60 | 7.40 | 16.34 | 11.07 | 24.14 | 70.08 | 71.72 | 11.52 | 23.16 | 1.04 | -- | 0.00 | 0.00 | 3.42 | 14.45 | 23.09 | 2.15 | -4.46 | -- |
| Zimmer Biomet Holdings Inc | 7.39bn | 1.02bn | 24.54bn | 18.00k | 24.43 | 1.97 | 12.41 | 3.32 | 4.89 | 4.89 | 35.26 | 60.70 | 0.3475 | 0.9195 | 5.24 | 410,794.40 | 4.82 | 2.21 | 5.49 | 2.52 | 71.82 | 71.25 | 13.86 | 7.28 | 0.7784 | 7.32 | 0.316 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| Resmed Inc | 4.50bn | 890.39m | 26.31bn | 10.14k | 29.63 | 5.87 | 24.56 | 5.84 | 6.04 | 6.04 | 30.53 | 30.47 | 0.6633 | 2.10 | 6.17 | 444,189.10 | 13.11 | 13.59 | 14.74 | 15.89 | 55.11 | 56.98 | 19.77 | 19.22 | 1.89 | 19.64 | 0.2149 | 36.66 | 18.02 | 12.53 | 15.15 | 14.63 | 13.40 | 4.68 |
| West Pharmaceutical Services Inc. | 2.95bn | 593.40m | 27.24bn | 10.60k | 47.20 | 9.49 | 38.20 | 9.23 | 7.88 | 7.88 | 39.19 | 39.20 | 0.7923 | 4.29 | 5.79 | 278,283.00 | 15.46 | 15.61 | 18.41 | 18.65 | 38.28 | 38.06 | 19.52 | 18.47 | 2.24 | -- | 0.067 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 57.93m | 11.40% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 29.66m | 5.84% |
| Dodge & Coxas of 31 Dec 2023 | 27.38m | 5.39% |
| Pzena Investment Management LLCas of 31 Dec 2023 | 24.27m | 4.78% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 21.36m | 4.20% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 15.46m | 3.04% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 13.75m | 2.71% |
| Geode Capital Management LLCas of 31 Dec 2023 | 11.09m | 2.18% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 9.58m | 1.89% |
| Harris Associates LPas of 31 Dec 2023 | 9.25m | 1.82% |
